UNSPSC 51332700: Antipsychotic dibenzazepines

Antipsychotic drugs made from compounds with two benzene rings fused to azepines.

UNSPSC 51332700 Antipsychotic dibenzazepines is a Class code that captures pharmaceutical products procured by state and local health agencies, though the recent solicitations tagged under this code diverge significantly from its nominal scope—the three most recent opportunities involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products rather than antipsychotic compounds specifically. State and local issuing bodies pursuing this code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances serving health systems and government employee populations. The work involves securing pharmaceutical supplies and establishing distribution or contracting relationships with manufacturers and wholesalers to support public health initiatives, community health programs, and state employee benefit plans.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program involving direct contracting with pharmaceutical manufacturers outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026, and awarded vendors effective July 1, 2026. All three solicitations reflect active procurement for pharmaceutical supply chains serving public health and government benefit populations.